Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/15/2017 06/16/2017 06/19/2017 06/20/2017 06/21/2017 Date
124.04(c) 123.14(c) 125.58(c) 126.33(c) 134.83(c) Last
1 017 745 3 152 299 1 509 058 1 737 625 3 239 802 Volume
-0.54% -0.73% +1.98% +0.60% +6.73% Change
More quotes
Financials ($)
Sales 2017 2 214 M
EBIT 2017 460 M
Net income 2017 312 M
Finance 2017 890 M
Yield 2017 -
Sales 2018 2 596 M
EBIT 2018 799 M
Net income 2018 604 M
Finance 2018 1 763 M
Yield 2018 -
P/E ratio 2017 102,00
P/E ratio 2018 59,44
EV / Sales2017 14,8x
EV / Sales2018 12,3x
Capitalization 33 582 M
More Financials
Company
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases.It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS
06/17 VERTEX PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Indiana (June 17)
06/15 VERTEX PHARMACEUTICALS : Patent Issued for Compounds Useful as Inhibitors of ATR..
06/15 Telephus Medical CEO Mark Benedyk Joins Pulmotect, Inc. Board of Directors
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
06/11 VERTEX PHARMACEUTICALS : in long-term reimbursement agreement with ROI for CF me..
06/10 VERTEX PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Indiana (June 10)
06/09 VERTEX PHARMACEUTICALS : Announces Long-Term Reimbursement Agreement with the Re..
06/09 VERTEX PHARMACEUTICALS : to Present at the Goldman Sachs Healthcare Conference o..
06/09 VERTEX PHARMACEUTICALS : Announces Nine Presentations of Data on ORKAMBI® (lumac..
06/08 VERTEX PHARMACEUTICALS INC / MA : Entry into a Material Definitive Agreement, Su..
More news
Sector news : Bio Therapeutic Drugs
06/21 Healthcare stocks rally as Senate set to unveil bill
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/21Big list of new highs today: $IMGN $CELG $REGN $VRTX $CLVS $FGEN $AKBA $PTCT ..
6
06/21We’re at a very unique moment in biomedical research & discovery, poised ..
3
06/21$VRTX Aug 140/150 call spreads being bought against sales of the 120 puts
3
06/21Analysts Anticipate Vertex Pharmaceuticals Incorporated $VRTX Will Post Quart.. 
06/20Today's Top 5 Technically Ranked Large Caps: $TSLA, $NVDA, $ATVI, $BABA, $VRT.. 
More tweets
Qtime:88
News from SeekingAlpha
06/21 Biotechs blaze as Trump draft order on drug prices would ease regulations
06/21 Biotech's Best Chance Has Gotten Even Better
06/21 Biotechs ripping, IBB up almost 8% in three days
06/08 Biotech's Best Chance!
06/02 Biotechs break through recent downtrend; IBB up 1%
Advertisement
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 126 $
Spread / Average Target -6,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith EVP, Chief Operating & Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Joshua S. Boger Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS83.02%31 465
AMGEN17.19%122 290
CELGENE CORPORATION14.76%98 556
GILEAD SCIENCES-5.74%85 708
REGENERON PHARMACEUTIC..34.93%52 649
ACTELION23.58%30 377
More Results